Anti-TNF-α therapy in patients with rheumatoid arthritis leads to the reduction of other pro-inflammatory mediators, such as IL-1β and IL-6, causing an improvement in the anti-inflammatory effect [121]. The gene discussed is IL6; the disease is rheumatoid arthritis.